Please ensure Javascript is enabled for purposes of website accessibility

Trump Signs $8.3 Billion Coronavirus Funding Measure

By Eric Volkman - Mar 6, 2020 at 4:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The emergency appropriation was ratified with wide bipartisan support in both the House of Representatives and the Senate.

President Donald Trump has signed an appropriations bill that allocates $8.3 billion to various arms of the federal government to fight the spread of SARS-CoV-2, the coronavirus that causes COVID-19. Trump's ratification of the Coronavirus Preparedness and Response Supplemental Appropriations Act came hard on the heels of its overwhelming bipartisan approvals in both the House of Representatives and the Senate.

Most of the funding will be channeled into the Department of Health and Human Services, to be dispersed to various branches involved in the effort to contain the rapidly spreading disease. Several other federal agencies will also receive monies for the same purpose, among them the State Department and the U.S. Agency for International Development (USAID).

President Tump, flanked by Secretary of Health and Human Services, signs the coronavirus bill into law.

President Trump, flanked by Secretary of Health and Human Services Alex Azar, signs the coronavirus bill into law. Image source: The White House

Following the signing, Trump flew to the Centers for Disease Control and Prevention (CDC) in Atlanta. This, despite a White House official's remarks Friday morning that the visit would not go ahead as planned.

According to the CDC, as of noon Friday, there were 164 confirmed cases of COVID-19 across 19 U.S. states, and 11 deaths in the country from the disease so far.

The spread of the coronavirus and its anticipated impacts on the economy continue to have a deleterious effect on the stock market; the major indexes again closed down notably on Friday.

Several biotech and pharmaceutical stocks directly involved in the fight, however, are doing well. Moderna (MRNA 2.58%), for one, rose by nearly 6% on the day. The company's efforts are focused on developing an RNA-based vaccine to prevent COVID-19. Moderna has received government funding to aid it in the process. Bloomberg reported today that a clinical trial for the Moderna vaccine candidate will start this month.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$159.56 (2.58%) $4.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
322%
 
S&P 500 Returns
113%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.